Skip to main content

Advertisement

Table 2 The relationship between clinicopathological factors and plasma VEGF levels

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

   Plasma VEGF Levels, pg/mL
Characteristics No. (%) Median 25-75% Quartile p Value
Age     
   <60 79 (59) 267.4 169.5 - 454.0 0.465
   >60 55 (41) 262.7 146.6-385.4  
Sex     
   Male 121 (90.3) 264.0 154.0 - 392.6 0.151
   Female 13 (9.7) 338.4 262.0 - 459.4  
Smoking     
   Smokers 108 (80.6) 273.9 173.7 - 442.7 0.144
   Never-smokers 26 (19.4) 257.1 120.7 - 354.5  
ECOG     
   1 39 (29.1) 225.7 108.6 - 354.5 0.062
   2-3 95 (70.9) 282.0 182.3 - 446.0  
Histology     
   SCC 103 (76.9) 276.0 169.5 - 439.5 0.147
   ADC 31 (23.1) 262.0 132.3 - 338.4  
Stage     
   III 87 (64.9) 251.4 149.0 - 433.4 0.250
   IV 47 (35.1) 276.0 214.0 - 399.4  
Tumor Size     
   <3 cm 44 (32.8) 172.4 93.0 - 262.0 0.001
   >3 cm 90 (67.2) 339.9 218.0 - 484.5  
T Factor     
   T2-T3 66 (49.2) 270.9 149.0 - 379.0 0.653
   T4 68 (50.8) 263.0 157.6 - 439.7  
N Factor     
   N0-N1 65 (48.5) 245.7 121.4 - 360.7 0.082
   N2-N3 69 (51.5) 285.7 192.0-439.5  
M Factor     
   M0 87 (64.9) 251.4 149.0 - 433.4 0.250
   M1 47 (35.1) 276.0 214.0 - 399.4  
Tobacco     
   Yes 25 (18.7) 252.3 185.7 - 354.5 0.524
   No 109 (81.3) 267.4 154.0 - 433.4  
  1. VEGF, vascular endothelial growth factor; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; ADC, adenocarcinoma; T, tumor; N, node; M, metastasis